Clinical Trials · NCT07225686

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Phase
Phase 3
Recruitment status
Recruiting
Sponsor
Amgen
Enrollment
250
Start date
Dec 2025
Locations
61 sites, 11 countries
Primary endpoint
Change in Apnea-Hypopnea Index (AHI) from baseline at week 52
View Maridebart-Cafraglutide compound reference